Liver function may change how evobrutinib works in the body
NCT ID NCT04546789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how different levels of liver impairment affect the way the body processes a single dose of the drug evobrutinib. Twenty-four participants with either normal liver function or mild to moderate liver impairment took one dose of the drug. Researchers measured drug levels in the blood and monitored safety. The goal was to understand if liver problems require dose adjustments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evobrutinib (a BTK inhibitor drug)
What this could lead to
If successful, this could help doctors decide the right dose of evobrutinib for people with liver problems.
What could go wrong
This is a very early, small study (24 people) focused on drug processing, not on treating a disease. Results may not apply to long-term use or to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Kiel GmbH
Kiel, Germany